JAK2 and acquired polycythemia vera: TP53 mutations were detected in three cases with AML-MRC.JAK2 V617F mutation was detected in secondary AMLs evolved from polycythemia vera and primary myelofibrosis, while one de novo AML (AML without maturation) case also harbored JAK2 V617F mutation.